Content Analysis of Informed Consent for Whole Genome Sequencing Offered by Direct-to-Consumer Genetic Testing Companies
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Content Analysis of Informed Consent for Whole Genome Sequencing Offered by Direct-to-Consumer Genetic Testing Companies. / Niemiec, Emilia; Borry, Pascal; Pinxten, Wim; Howard, Heidi Carmen.
In: Human Mutation, Vol. 37, No. 12, 01.12.2016, p. 1248-1256.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Content Analysis of Informed Consent for Whole Genome Sequencing Offered by Direct-to-Consumer Genetic Testing Companies
AU - Niemiec, Emilia
AU - Borry, Pascal
AU - Pinxten, Wim
AU - Howard, Heidi Carmen
N1 - Publisher Copyright: © 2016 WILEY PERIODICALS, INC.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Whole exome sequencing (WES) and whole genome sequencing (WGS) have become increasingly available in the research and clinical settings and are now also being offered by direct-to-consumer (DTC) genetic testing (GT) companies. This offer can be perceived as amplifying the already identified concerns regarding adequacy of informed consent (IC) for both WES/WGS and the DTC GT context. We performed a qualitative content analysis of Websites of four companies offering WES/WGS DTC regarding the following elements of IC: pre-test counseling, benefits and risks, and incidental findings (IFs). The analysis revealed concerns, including the potential lack of pre-test counseling in three of the companies studied, missing relevant information in the risks and benefits sections, and potentially misleading information for consumers. Regarding IFs, only one company, which provides opportunistic screening, provides basic information about their management. In conclusion, some of the information (and related practices) present on the companies’ Web pages salient to the consent process are not adequate in reference to recommendations for IC for WGS or WES in the clinical context. Requisite resources should be allocated to ensure that commercial companies are offering high-throughput sequencing under responsible conditions, including an adequate consent process.
AB - Whole exome sequencing (WES) and whole genome sequencing (WGS) have become increasingly available in the research and clinical settings and are now also being offered by direct-to-consumer (DTC) genetic testing (GT) companies. This offer can be perceived as amplifying the already identified concerns regarding adequacy of informed consent (IC) for both WES/WGS and the DTC GT context. We performed a qualitative content analysis of Websites of four companies offering WES/WGS DTC regarding the following elements of IC: pre-test counseling, benefits and risks, and incidental findings (IFs). The analysis revealed concerns, including the potential lack of pre-test counseling in three of the companies studied, missing relevant information in the risks and benefits sections, and potentially misleading information for consumers. Regarding IFs, only one company, which provides opportunistic screening, provides basic information about their management. In conclusion, some of the information (and related practices) present on the companies’ Web pages salient to the consent process are not adequate in reference to recommendations for IC for WGS or WES in the clinical context. Requisite resources should be allocated to ensure that commercial companies are offering high-throughput sequencing under responsible conditions, including an adequate consent process.
KW - consumer genomics
KW - direct-to-consumer genetic testing
KW - informed consent
KW - whole exome sequencing
KW - whole genome sequencing
UR - http://www.scopus.com/inward/record.url?scp=84990847986&partnerID=8YFLogxK
U2 - 10.1002/humu.23122
DO - 10.1002/humu.23122
M3 - Journal article
C2 - 27647801
AN - SCOPUS:84990847986
VL - 37
SP - 1248
EP - 1256
JO - Human Mutation
JF - Human Mutation
SN - 1059-7794
IS - 12
ER -
ID: 369542630